FibroGen Current Deferred Revenue vs Common Stock Shares Outstanding Analysis

FGEN Stock

USD 1.20 0.05 4.35%

FibroGen financial indicator trend analysis is much more than just examining FibroGen latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether FibroGen is a good investment. Please check the relationship between FibroGen Current Deferred Revenue and its Common Stock Shares Outstanding accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.

To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.

Current Deferred Revenue vs Common Stock Shares Outstanding

Current Deferred Revenue vs Common Stock Shares Outstanding Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of FibroGen Current Deferred Revenue account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between FibroGen's Current Deferred Revenue and Common Stock Shares Outstanding is 0.44. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of FibroGen, assuming nothing else is changed. The correlation between historical values of FibroGen's Current Deferred Revenue and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of FibroGen are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Current Deferred Revenue i.e., FibroGen's Current Deferred Revenue and Common Stock Shares Outstanding go up and down completely randomly.

Correlation Coefficient

0.44

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Most indicators from FibroGen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into FibroGen current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.

To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.As of the 1st of June 2024, Selling General Administrative is likely to drop to about 82.7 M. In addition to that, Tax Provision is likely to drop to about 29.4 K

	2021	2022	2023	2024 (projected)
Interest Expense	2.2M	1.4M	15.5M	16.3M
Depreciation And Amortization	14.8M	18.2M	9.9M	9.5M

Interest Expense Depreciation And Amortization

FibroGen fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross
Total Assets		-0.37	0.35	0.45	0.64	0.6	-0.36	0.35	-0.59	-0.4	0.44	0.6	-0.23	0.23	0.32	-0.7	0.96	0.52	0.78	0.65	0.64	0.54	0.34	0.76	0.51	-0.34
Short Long Term Debt Total	-0.37		0.14	0.16	-0.61	0.23	0.21	0.45	0.48	-0.33	-0.03	-0.37	0.06	-0.47	-0.72	0.1	-0.36	0.02	0.07	0.02	-0.08	0.38	-0.35	0.04	0.28	0.96
Other Current Liab	0.35	0.14		0.96	-0.27	0.85	-0.6	0.53	-0.02	-0.84	0.91	0.05	-0.37	-0.45	0.03	-0.02	0.33	0.38	0.68	0.72	0.42	0.8	0.09	0.76	0.91	0.12
Total Current Liabilities	0.45	0.16	0.96		-0.22	0.93	-0.58	0.65	-0.16	-0.88	0.95	0.2	-0.36	-0.4	0.05	-0.15	0.45	0.34	0.8	0.79	0.39	0.9	0.03	0.85	0.98	0.13
Total Stockholder Equity	0.64	-0.61	-0.27	-0.22		-0.06	0.11	-0.16	-0.61	0.41	-0.16	0.54	0.08	0.6	0.52	-0.48	0.62	0.22	0.2	0.06	0.32	-0.16	0.32	0.14	-0.19	-0.57
Other Liab	0.6	0.23	0.85	0.93	-0.06		-0.6	0.64	-0.25	-0.87	0.81	0.31	-0.45	-0.34	0.01	-0.36	0.61	0.5	0.93	0.86	0.49	0.97	0.16	0.95	0.97	0.26
Property Plant And Equipment Net	-0.36	0.21	-0.6	-0.58	0.11	-0.6		0.04	0.29	0.67	-0.58	-0.3	0.73	0.44	-0.38	0.16	-0.42	-0.47	-0.55	-0.66	-0.18	-0.44	-0.41	-0.63	-0.52	0.05
Current Deferred Revenue	0.35	0.45	0.53	0.65	-0.16	0.64	0.04		0.0	-0.57	0.6	0.07	0.13	-0.29	-0.18	-0.27	0.3	0.36	0.63	0.44	0.33	0.78	-0.41	0.56	0.73	0.34
Net Debt	-0.59	0.48	-0.02	-0.16	-0.61	-0.25	0.29	0.0		0.01	-0.27	-0.99	0.36	-0.09	-0.76	0.26	-0.71	-0.08	-0.39	-0.26	0.16	-0.11	0.06	-0.37	-0.14	0.42
Retained Earnings	-0.4	-0.33	-0.84	-0.88	0.41	-0.87	0.67	-0.57	0.01		-0.78	-0.09	0.48	0.53	0.17	0.24	-0.41	-0.43	-0.74	-0.79	-0.39	-0.88	-0.09	-0.81	-0.9	-0.34
Accounts Payable	0.44	-0.03	0.91	0.95	-0.16	0.81	-0.58	0.6	-0.27	-0.78		0.29	-0.33	-0.45	0.27	-0.05	0.45	0.32	0.7	0.75	0.28	0.77	-0.12	0.78	0.88	-0.07
Cash	0.6	-0.37	0.05	0.2	0.54	0.31	-0.3	0.07	-0.99	-0.09	0.29		-0.39	0.01	0.69	-0.28	0.72	0.09	0.44	0.29	-0.18	0.18	-0.11	0.4	0.19	-0.31
Non Current Assets Total	-0.23	0.06	-0.37	-0.36	0.08	-0.45	0.73	0.13	0.36	0.48	-0.33	-0.39		0.46	-0.28	0.13	-0.43	-0.42	-0.33	-0.54	-0.11	-0.32	-0.15	-0.48	-0.35	-0.06
Non Currrent Assets Other	0.23	-0.47	-0.45	-0.4	0.6	-0.34	0.44	-0.29	-0.09	0.53	-0.45	0.01	0.46		-0.05	-0.34	0.11	-0.38	-0.14	-0.29	0.19	-0.34	0.5	-0.23	-0.38	-0.52
Other Assets	0.32	-0.72	0.03	0.05	0.52	0.01	-0.38	-0.18	-0.76	0.17	0.27	0.69	-0.28	-0.05		0.04	0.41	0.2	0.13	0.11	-0.2	-0.16	-0.06	0.13	-0.06	-0.63
Long Term Debt	-0.7	0.1	-0.02	-0.15	-0.48	-0.36	0.16	-0.27	0.26	0.24	-0.05	-0.28	0.13	-0.34	0.04		-0.65	-0.44	-0.54	-0.5	-0.57	-0.36	-0.42	-0.54	-0.26	0.05
Cash And Short Term Investments	0.96	-0.36	0.33	0.45	0.62	0.61	-0.42	0.3	-0.71	-0.41	0.45	0.72	-0.43	0.11	0.41	-0.65		0.53	0.76	0.67	0.54	0.53	0.24	0.77	0.5	-0.32
Net Receivables	0.52	0.02	0.38	0.34	0.22	0.5	-0.47	0.36	-0.08	-0.43	0.32	0.09	-0.42	-0.38	0.2	-0.44	0.53		0.55	0.57	0.64	0.46	0.15	0.57	0.41	0.13
Common Stock Total Equity	0.78	0.07	0.68	0.8	0.2	0.93	-0.55	0.63	-0.39	-0.74	0.7	0.44	-0.33	-0.14	0.13	-0.54	0.76	0.55		0.79	0.55	0.9	0.24	0.94	0.87	0.11
Common Stock Shares Outstanding	0.65	0.02	0.72	0.79	0.06	0.86	-0.66	0.44	-0.26	-0.79	0.75	0.29	-0.54	-0.29	0.11	-0.5	0.67	0.57	0.79		0.59	0.81	0.25	0.95	0.82	0.05
Short Term Investments	0.64	-0.08	0.42	0.39	0.32	0.49	-0.18	0.33	0.16	-0.39	0.28	-0.18	-0.11	0.19	-0.2	-0.57	0.54	0.64	0.55	0.59		0.51	0.49	0.59	0.46	-0.1
Non Current Liabilities Total	0.54	0.38	0.8	0.9	-0.16	0.97	-0.44	0.78	-0.11	-0.88	0.77	0.18	-0.32	-0.34	-0.16	-0.36	0.53	0.46	0.9	0.81	0.51		0.04	0.9	0.97	0.36
Other Current Assets	0.34	-0.35	0.09	0.03	0.32	0.16	-0.41	-0.41	0.06	-0.09	-0.12	-0.11	-0.15	0.5	-0.06	-0.42	0.24	0.15	0.24	0.25	0.49	0.04		0.25	0.03	-0.23
Other Stockholder Equity	0.76	0.04	0.76	0.85	0.14	0.95	-0.63	0.56	-0.37	-0.81	0.78	0.4	-0.48	-0.23	0.13	-0.54	0.77	0.57	0.94	0.95	0.59	0.9	0.25		0.9	0.07
Total Liab	0.51	0.28	0.91	0.98	-0.19	0.97	-0.52	0.73	-0.14	-0.9	0.88	0.19	-0.35	-0.38	-0.06	-0.26	0.5	0.41	0.87	0.82	0.46	0.97	0.03	0.9		0.25
Property Plant And Equipment Gross	-0.34	0.96	0.12	0.13	-0.57	0.26	0.05	0.34	0.42	-0.34	-0.07	-0.31	-0.06	-0.52	-0.63	0.05	-0.32	0.13	0.11	0.05	-0.1	0.36	-0.23	0.07	0.25

Click cells to compare fundamentals

FibroGen Account Relationship Matchups

FibroGen fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	857.4M	826.8M	773.8M	610.1M	423.5M	665.2M
Short Long Term Debt Total	51.1M	37.7M	99.7M	89.9M	170.5M	103.2M
Other Current Liab	83.8M	119.5M	172.6M	219.4M	172.9M	86.8M
Total Current Liabilities	102.7M	163.2M	225.5M	273.6M	217.7M	128.8M
Total Stockholder Equity	516.1M	422.2M	209.1M	(21.4M)	(204.2M)	(194.0M)
Other Liab	162.8M	178.1M	212.8M	241.4M	277.6M	147.1M
Property Plant And Equipment Net	82.3M	63.3M	120.2M	100.5M	81.4M	89.5M
Current Deferred Revenue	490K	6.5M	15.9M	13.1M	12.7M	10.0M
Net Debt	(75.2M)	(640.7M)	(71.5M)	(65.8M)	56.8M	59.6M
Retained Earnings	(784.7M)	(974.0M)	(1.3B)	(1.6B)	(1.8B)	(1.7B)
Accounts Payable	6.1M	24.8M	26.1M	30.8M	18.0M	13.0M
Cash	126.3M	678.4M	171.2M	155.7M	113.7M	108.0M
Non Current Assets Total	154.9M	71.7M	299.8M	117.3M	92.0M	146.7M
Non Currrent Assets Other	11.4M	5.5M	8.0M	7.4M	3.6M	6.4M
Other Assets	9.5M	38.1M	8.0M	6.9M	1.0	0.95
Long Term Debt	17.2M	16.8M	16.8M	71.9M	64.7M	46.3M
Cash And Short Term Investments	533.8M	686.5M	405.2M	422.0M	235.6M	404.9M
Net Receivables	28.5M	41.9M	17.4M	16.3M	41.1M	25.9M
Common Stock Total Equity	854K	877K	914K	929K	1.1M	716.1K
Common Stock Shares Outstanding	86.6M	89.9M	92.3M	93.6M	97.3M	78.2M
Short Term Investments	407.5M	8.1M	234.0M	266.3M	121.9M	165.1M
Liabilities And Stockholders Equity	857.4M	826.8M	773.8M	610.1M	423.5M	665.2M
Non Current Liabilities Total	219.2M	222.2M	319.2M	338.0M	368.1M	261.8M
Other Current Assets	133.4M	1.8M	5.1M	4.4M	13.4M	17.1M
Other Stockholder Equity	1.3B	1.4B	1.5B	1.5B	1.6B	1.0B
Total Liab	322.0M	385.4M	544.7M	611.6M	585.7M	390.6M
Property Plant And Equipment Gross	82.3M	63.3M	120.2M	100.5M	253.1M	138.8M
Total Current Assets	702.5M	755.1M	474.1M	492.8M	331.6M	463.5M
Accumulated Other Comprehensive Income	(747K)	(4.5M)	(4.2M)	(5.7M)	(6.9M)	(6.5M)
Short Term Debt	12.4M	12.3M	11.0M	10.3M	14.1M	19.1M
Common Stock	877K	914K	929K	942K	988K	773.7K
Property Plant Equipment	42.7M	33.6M	120.2M	100.9M	90.8M	86.7M
Net Tangible Assets	516.1M	422.2M	209.1M	(21.4M)	(19.3M)	(18.3M)
Long Term Investments	61.1M	244K	171.6M	9.4M	5.3M	5.0M
Retained Earnings Total Equity	(715.8M)	(784.7M)	(974.0M)	(1.3B)	(1.1B)	(1.2B)
Capital Surpluse	1.2B	1.3B	1.4B	1.5B	1.7B	1.2B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether FibroGen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of FibroGen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fibrogen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fibrogen Stock:

How To Invest In FibroGen

Details

Is FibroGen Stock a good investment?

Details

What is FibroGen's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.

To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.

Note that the FibroGen information on this page should be used as a complementary analysis to other FibroGen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for FibroGen Stock analysis

When running FibroGen's price analysis, check to measure FibroGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroGen is operating at the current time. Most of FibroGen's value examination focuses on studying past and present price action to predict the probability of FibroGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroGen's price. Additionally, you may evaluate how the addition of FibroGen to your portfolios can decrease your overall portfolio volatility.

	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios

Is FibroGen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.536

Earnings Share

(2.44)

Revenue Per Share

1.703

Quarterly Revenue Growth

0.546

Return On Assets

(0.34)

The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

FibroGen Current Deferred Revenue vs Common Stock Shares Outstanding Analysis

Current Deferred Revenue vs Common Stock Shares Outstanding

Current Deferred Revenue vs Common Stock Shares Outstanding Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Common Stock Shares Outstanding

FibroGen fundamental ratios Correlations

FibroGen Account Relationship Matchups

High Positive Relationship

High Negative Relationship

FibroGen fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for FibroGen Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 0.98	Total Current Liabilities
Non Current Liabilities Total	+ 0.97	Other Liab
Total Liab	+ 0.97	Other Liab
Total Liab	+ 0.97	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.96	Total Assets
Property Plant And Equipment Gross	+ 0.96	Short Long Term Debt Total

Cash	- 0.99	Net Debt
Total Liab	- 0.9	Retained Earnings
Non Current Liabilities Total	- 0.88	Retained Earnings
Retained Earnings	- 0.88	Total Current Liabilities
Retained Earnings	- 0.87	Other Liab
Retained Earnings	- 0.84	Other Current Liab